Literature DB >> 22763968

Comparison of the sensitivity and specificity of real-time PCR and in situ hybridization in HPV16 and 18 detection in archival cervical cancer specimens.

Beata Biesaga1, Sława Szostek, Małgorzata Klimek, Jerzy Jakubowicz, Joanna Wysocka.   

Abstract

The aim of this study was to analyze the correlation between real-time PCR (RT-PCR) treated as a reference method and in situ hybridization with tyramide amplification system (ISH-TSA) in the detection of HPV16 and 18 infection and the assessment of viral genome status. The study was performed on cervical cancer biopsies fixed in 10% neutral buffered formalin and embedded in paraffin obtained from 85 women. TaqMan-based 5'exonuclease RT-PCR with type-specific primers was used to assess HPV16 and 18 infections and genome status. Viral infection and genome status was also assessed by ISH-TSA. RT-PCR revealed 76 (89.4%), and ISH-TSA 81 (95.3%) cancers with HPV16 and 18 infections. The ISH-TSA sensitivity and specificity were: 96.1% and 11.1% compared to RT-PCR. The difference between these techniques in HPV detection was significant (p = 0.000). Among 76 HPV16/18 positive cancers in RT-PCR, there were 30 (39.5%) with integrated and 46 (60.5%) with mixed viral genome form. According to ISH-TSA, there were 39 (51.3%) samples with integrated and 37 with mixed form (48.7%). The sensitivity and specificity of ISH-TSA in genome status assessment were 70.0% and 60.9%, respectively. The difference between RT-PCR and ISH-TSA in genome state detection was not statistically significant (p = 0.391). These results suggest that ISH-TSA shows insufficient specificity in HPV detection for use in clinical practice. However, this assay could be applied for viral genome status assessment.

Entities:  

Mesh:

Year:  2012        PMID: 22763968     DOI: 10.5603/fhc.2012.0033

Source DB:  PubMed          Journal:  Folia Histochem Cytobiol        ISSN: 0239-8508            Impact factor:   1.698


  2 in total

1.  Methylation of the L1 gene and integration of human papillomavirus 16 and 18 in cervical carcinoma and premalignant lesions.

Authors:  Francisco Israel Torres-Rojas; Luz Del Carmen Alarcón-Romero; Marco Antonio Leyva-Vázquez; Julio Ortiz-Ortiz; Miguel Ángel Mendoza-Catalán; Daniel Hernández-Sotelo; Oscar Del Moral-Hernández; Hugo Alberto Rodríguez-Ruiz; Dinorah Leyva-Illades; Eugenia Flores-Alfaro; Berenice Illades-Aguiar
Journal:  Oncol Lett       Date:  2017-12-13       Impact factor: 2.967

2.  Differences in the prognosis of HPV16-positive patients with squamous cell carcinoma of head and neck according to viral load and expression of P16.

Authors:  Beata Biesaga; Anna Mucha-Małecka; Anna Janecka-Widła; Marta Kołodziej-Rzepa; Sława Szostek; Dorota Słonina; Aleksandra Kowalczyk; Krzysztof Halaszka; Marcin Przewoźnik
Journal:  J Cancer Res Clin Oncol       Date:  2017-10-17       Impact factor: 4.553

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.